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BRIEF COMMUNICATION
Unlike the more commonly encountered small-
cell neuroendocrine carcinoma (SCNEC) of neu-
roendocrine cervical carcinoma (NECC), large-cell
neuroendocrine carcinoma (LCNEC) of the uter-
ine cervix is a very rare malignancy. A literature
search reveals no more than 30 cases of LCNEC
reported worldwide. We retrieved individual med-
ical information of all cases with LCNEC from
Mackay Memorial Hospital (MMH) and Veterans
General Hospital (VGH). After careful review and
classification, we present our experience with seven
cases with regard to diagnosis, treatment, and
prognosis of this disease type. This is the largest
published series of LCNEC with reported HPV
status to date. The importance of human papillo-
mavirus (HPV) infection is now widely recog-
nized, and is considered a necessary cause for
over 99% of cervical carcinogenesis.1,2 The purpose
of this study was to investigate the role of HPV
subtype(s) on the survival of patients, and its
correlation with clinical parameters of HPV status
or survival outcomes.
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Large-cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is a very rare malignancy. We
aimed to investigate the role of human papillomavirus (HPV) on the survival of patients, and its cor-
relation with clinical parameters of HPV status or survival outcomes. Only seven cases of LCNEC were
retrospectively collected among 8018 (0.087%) invasive cervical carcinomas from the cancer registry
systems at Mackay Memorial Hospital and Veterans General Hospital over a period of 17 years. The
median survival time was 17.2 months, including only one long-term survivor (> 5 years). The 2-year
and 5-year survival rates after diagnosis were 42% and 30%, respectively. The results indicated that the
majority of LCNEC cases were dominated by high-risk HPV-18. No clinical parameters appeared to be
associated with HPV-18 or survival outcomes of LCNEC patients. Pelvic lymph node metastasis positiv-
ity could also be considered as a prognostic factor for this disease. [J Formos Med Assoc 2009;
108(5):428–432]
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Methods
Individual subject data were retrospectively col-
lected from the cancer registry systems at MMH
and VGH between January 1, 1991 and October
31, 2007. A total of 8018 patients were identified
with cervical cancer during this same period in
these hospitals. All patients identified as NECC
or LCNEC in the original pathology reports were
at first retrieved from the cancer registry systems.
Patients identified as “NECC of the uterine cervix”
were then further classified into one of the four
histopathologic types as proposed by Albores-
Saavedra et al3 in 1997: typical carcinoid tumor,
atypical carcinoid tumor, SCNEC and LCNEC.
The selection and reassignment of patients was
performed by gynecologic pathologists of respec-
tive medical institutions. Additional criteria used
for diagnosing NECC tumors were based on im-
munohistochemical staining results of three neu-
roendocrine markers (neuron specific enolase,
chromogranin, and synaptophysin). Cases other
than LCNEC disease type were excluded from the
selected cases. All the paraffin-embedded tissue
blocks and their corresponding hematoxylin and
eosin-stained sections were collected.
Clinical histories on the patients were care-
fully reviewed. Relevant clinical data included 
all past HPV-related events (e.g. Pap test, biop-
sies, or HPV tests), and any test results related 
to these medical events were extracted directly
from chart review of records of clinic visits as
well as correspondence with patients and physi-
cians. Overall survival was defined as the time
from initial diagnosis to the time of death or 
last follow-up. All surviving patients were followed-
up until December 31, 2007. The study was 
approved by the respective institutional review
boards and ethics committees of the participat-
ing hospitals.
The genomic DNA for HPV typing was extracted
from paraffin-embedded tissue blocks using the
commercially available DNeasy Tissue Kit (Qiagen,
Hilden, Germany). Sections were deparaffinized
and screened for HPV DNA by L1 consensus PCR
(primers MY11/GP61) and HPV 16/18 DNA by
PCR amplification, using HPV 16 and 18 specific
primers.4,5
Significance levels for association between cat-
egorical variables in different groups were assessed
using Pearson’s χ2 or Fisher’s exact tests as appro-
priate. Survival analysis of patients with LCNEC
was evaluated using the Kaplan-Meier method. All
statistical tests were performed with SPSS version
R13 (SPSS Inc., Chicago, IL, USA). Means are pre-
sented with their standard deviations. All signifi-
cance levels (p values) corresponded to two-sided
tests (α = 0.05).
Results
The clinical characteristics, treatment modalities
and outcome data of the seven patients with
LCNEC diseases are listed in the Table. All patients
were female with a mean age of 42.3 ± 10.9 years
(median, 41 years; range, 28–62 years) at initial di-
agnosis. Mean tumor diameter was 3.07 ± 1.17 cm.
Tumors were clinically staged as FIGO (Inter-
national Federation of Gynecology and Obstetrics)
stage IA2 (1/7, 14%), stage IB1 (4/7, 57%), and
stage IB2 (2/7, 29%). Most patients were treated
initially with radical hysterectomy (RH) (6/7,
86%), with bilateral pelvic lymph node dissec-
tion (BPLD) and para-aortic lymphadenectomy
(PALD). Two patients received only RH (2/7), but
the other patients (4/7) had postoperative adju-
vant treatments: chemotherapy (CT) (2/7); and CT
plus radiotherapy (RT) (2/7). Only one patient
(1/7) received non-RH surgery, bilateral salpingo-
oophorectomy with PALD and BPLD, followed
by postoperative adjuvant CT + RT. Adjuvant CT
included carboplatin, VEP (etoposide, epiru-
bicin, cisplatin), EP (epirubicin, cisplatin), and
VP (etoposide, cisplatin).
HPV DNA was detected in 6/7 paraffin tissues
of examined LCNEC patients, where HPV-18 was
found as a single infection. Four patients exhib-
ited pure-type histologic pattern (4/7), and three
exhibited mixed-type histologic pattern (3/7).
Three patients were confirmed to be positive for
pelvic lymph node (LNP) metastasis (3/7), and
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two of these patients were also confirmed to 
be positive for para-aortic lymph node LNPA
metastasis (2/7).
Treatment responses and long-term survival for
patients with LCNEC were disappointing. The
mean survival times were 43.8 months (median,
17.2 months; range, 3–114 months), 15.6 months
(median, 11.8 months; range, 3–39 months),
and 49.1 months (median, 17.2 months; range,
3–114 months) for all patients, expired patients,
and patients who underwent RH, respectively.
Only two of these patients remain alive (2/7,
29%). These survivors were diagnosed as FIGO
stages IA2 and IB1. These two patients were both
diagnosed with HPV-18 and confirmed to be nega-
tive for both LNP and LNPA metastases (2/7), ex-
hibiting mixed-type histologic pattern without
evidence of recurrence. One patient was a long-
term survivor (>5 years) with a survival time of 114
months. All patients with confirmed LNPA metas-
tases were also associated with confirmed LNP
metastases. The 2-year and 5-year survival rates
after diagnosis were 42% and 30% for patients
with LCNEC diseases (Figure).
The presence of HPV-18 was not associated
with any clinicopathologic parameters: age groups,
clinical stage, tumor histology, surgical methods,
lymph node status, and chemotherapeutic regi-
mens. Additional analyses, however, reveal no
statistical significance for LCNEC patients with
HPV-18 and pure-type histologic pattern, alone
or in combination.
Discussion
The analyses described in this study extend the
scope of a recent study.6 Only seven clinical cases
with LCNEC disease were found among 8018
(0.087%) invasive cervical carcinoma at MMH
and VGH over a period of 17 years, which demon-
strates the extreme rarity of this histologic type.
In this study, our experience shows that the ma-
jority of cases are dominated by high-risk HPV-
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Figure. Kaplan-Meier survival curves for patients with
large-cell neuroendocrine carcinoma diseases (n = 7).
Table. Clinical characteristics, treatment modalities and outcome data of LCNEC patients (n = 7)
Case Age (yr)
FIGO Primary Tumor HPV Adjuvant Site of
Follow-up (mo)
stage treatment size (cm) type therapy recurrence
1 37 IA2 RH 3 18 EP – NED (35.2)
2 28 IB1 RH 3.5 18 VEP Lung, bone DOD (17.2)
3 35 IB1 RH 3 18 RT, EP Bone, pancreas DOD (39.0)
4 45 IB1 RH 3 18 RT, EP Bone, brain, DOD (3.0)
lungs, skin,
pancreas
5 48 IB1 RH 3 18 – – NED (114.3)
6 41 IB2 RH 1 18 – – DOD (7.0)
7 62 IB2 BSO 5 – RT, VP Lung DOD (11.8)
LCNEC = large-cell neuroendocrine carcinoma; FIGO = International Federation of Gynecology and Obstetrics; HPV = human papillomavirus; RH = radical
hysterectomy; BSO = bilateral salpingo-oophorectomy; EP = epirubicin+ cisplatin; VEP = etoposide+ epirubicin+ cisplatin; RT = radiotherapy; VP = etoposide +
cisplatin; NED = no evidence of disease; DOD = died of disease.
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clinicopathologic parameters. Unlike primary
tumor size, pelvic lymph node metastasis posi-
tivity can be considered a prognostic factor for
LCNEC disease.
The presence of lymph node metastasis has
been reported to be an adverse prognostic factor
at time of surgery in early-stage LCNEC patients,
which is consistent with our results.7 Frequent ex-
trapelvic spread of LCNEC tumor has been re-
ported to render very poor treatment outcome,
despite aggressive therapy.8 LCNEC patients with-
out confirmed pelvic LNP metastasis had better
survival outcome with a mean survival time of
67.7 months (median, 39 months; range, 3–114
months); whereas the mean survival time of those
with confirmed LNP metastasis was approximately
one-fourth of those without it—a mean survival
time of 12 months (median, 12 months; range,
7–17 months).
In our study, primary tumor size had no impact
on the survival of LCNEC patients. According to
the work by Bermudez et al,9 no recurrence
would occur when the tumor sizes of NECC were
less than 4 cm in diameter, and tumors exhibiting
mixed-type histologic pattern were over 4 cm in di-
ameter in all cases, which did not agree with our
observations on LCNEC. Three out of four recur-
rences (3/4) in the current study had tumor sizes
less than 4 cm in diameter; and only one recur-
rence had tumor size of 5 cm in diameter. More-
over, no patient had mixed-type tumors of over
4 cm in diameter with a mean size of 2.3 cm; on
the contrary, only one patient with pure-type tu-
mors (1/7) had tumor of over 4 cm in diameter
with a mean size of 3.3 cm.
Our data supports the presence of a single HPV
infection (HPV-18) in LCNEC disease, which is
inconsistent with the results reported by Grayson
et al,10 Powell and McKinney,11 and Yun et al.12
These authors concluded that HPV-16 was the
major subtype associated with LCNEC disease.
However, in our series, six LCNEC patients had
HPV viral infection (6/7, 86%), whereas Grayson
et al10 detected a slightly lower percentage of 75%
(9/12). Our findings agree with those of many re-
searchers in Taiwan.13–15 At present, we are unable
to provide explanation for the discrepancy be-
tween the predomination of the HPV-18 subtype
in Taiwan and the rest of the world, except to at-
tribute it to regional-specific distribution of HPV.
This controversy will remain an ongoing topic of
investigation for us.
In conclusion, this study confirms the presence
of high-risk HPV-18 in patients with LCNEC dis-
ease. Confirmed LNP status can be considered a
prognostic factor for this disease. Primary tumor
size, age groups, surgical methods, chemothera-
peutic regimens, and LNPA involvement do not ap-
pear to be associated with survival outcomes of
LCNEC patients. We hope that our seven-case expe-
rience on the diagnosis, treatment, and prognosis
of LCNEC diseases may contribute to improving
clinical decision making for patients with this rare
disease.
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